Ophthalmology billing: intravitreal injections, cataract globals, and premium IOLs

The bottom line

Ophthalmology denials concentrate in three places: laterality on intravitreal injections, complex cataract cases documented in generic language, and premium IOL upgrades billed as though Medicare might cover part of the upgrade.

The premium IOL section is the one to read even if you skip everything else, because the conventional advice on it is wrong in three specific ways, including a code that is widely cited as the premium lens code and is actually the covered conventional lens.

Definitions and frequently used terms

Laterality modifier. RT, LT, or 50, identifying which eye. In this specialty it is not a formality.

Global period. The window after a surgery during which related follow-up is included in the surgical payment. Cataract surgery carries a 90-day global.

LCA. Local Coverage Article. Issued by a Medicare Administrative Contractor for its own jurisdiction, not by CMS nationally. This distinction matters more in ophthalmology than almost anywhere else, and I will come back to it.

MAC. Medicare Administrative Contractor. The regional contractor that processes your Medicare claims and issues the LCDs and LCAs you are actually subject to.

Statutory exclusion. A service Medicare is not permitted to cover by law, as opposed to one denied as not reasonable and necessary. The difference determines whether an ABN is required. It comes up below.

CARC and RARC. Claim Adjustment Reason Code and Remittance Advice Remark Code. The CARC gives the category, the RARC the detail.

Why this specialty bills differently

Ophthalmology combines high-volume outpatient surgery, chronic disease management, diagnostic imaging, and elective patient-pay technology in one practice. A mid-sized retina or cataract practice generates claims across cataract extraction, intravitreal injections paired with high-cost drugs, diagnostic imaging with its own frequency rules, and routine eye exams, in the same week, each governed by different rules.

Two features drive most of the complexity.

Paired procedure and drug billing. Every intravitreal injection is two linked claim lines: the administration code and the drug J-code, each with its own laterality, units calculation, and medical necessity diagnosis. If the drug is denied as not reasonable and necessary, the injection code goes down with it. Very few specialties carry that compounding risk at this volume.

Global periods that collide with normal care. Cataract patients come back for second-eye surgery, YAG capsulotomy, and unrelated glaucoma or retina care inside the 90-day window of the first procedure. Sorting a related complication from a staged procedure from an unrelated one requires documentation that most outpatient visits never need.

Intravitreal injections

Laterality

CPT 67028 needs a laterality modifier. Missing or mismatched laterality is a leading and entirely preventable denial in this specialty, and it is worth building a hard scrubber edit for.

NOTE on where that rule comes from, because it is usually cited incorrectly. The frequently quoted language, that claims for 67028 without the appropriate site modifier “will be returned to the provider unprocessed,” comes from Local Coverage Article A52451, which is issued by Wellpoint Federal and applies only to Jurisdiction 6 (Illinois, Minnesota, Wisconsin) and Jurisdiction K (Connecticut, New York, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont).

It is not national CMS policy, and calling it that gives a two-jurisdiction article force it does not have. If you are in Novitas, Palmetto, Noridian, WPS, First Coast, or CGS territory, find your own MAC's article. The practical guidance is the same almost everywhere. The citation is not.

IMPORTANT: the requirement I can source applies to the 67028 line. The common advice to carry matching laterality on the drug J-code line is sensible operational practice and many payers do expect it, but I could not find it in A52451 or any CMS source. So do it, and confirm it with your own MAC, but do not cite A52451 for it in an appeal.

Bilateral same-day injections

67028 carries MPFS bilateral surgery indicator 1. For bilateral same-day injections Medicare Part B wants one line, modifier 50, one unit, fee doubled, paid at 150% of the unilateral allowable.

Submitting RT and LT on separate lines commonly produces a duplicate-line denial on the second eye rather than a clean bilateral adjustment, so line construction still matters. What it does not do is quietly pay you 125%. Under indicator 1 the bilateral adjustment is applied by the payment system regardless of how the claim arrives, and there is no construction under Medicare's rules that yields 125%. If you have seen that figure quoted, it does not trace to any MPFS rule I could locate.

In an ASC setting, confirm payer preference, since some contractors want RT and LT lines there.

The drug codes

The four most commonly cited are J0178 (aflibercept), J2778 (ranibizumab), J0179 (brolucizumab-dbll), and J2777 (faricimab-svoa).

IMPORTANT: that list is incomplete for 2026 practice. A52451's current code list also includes J0177 (aflibercept HD), J2779 (ranibizumab via the Susvimo implant), and ten biosimilars: Q5124, Q5128, Q5168 for ranibizumab and Q5147, Q5149, Q5150, Q5153, Q5155, Q5170 for aflibercept. A practice billing only the original four is working from a stale list, and biosimilar mix is exactly where step therapy pushes patients.

Note also that compounded bevacizumab, the drug most step therapy protocols require you to try first, is not on A52451 at all and bills differently. If your workflow discusses bevacizumab failure but your charge master has no way to bill bevacizumab, that gap is worth closing.

Record the full drug administration detail on every injection: drug name, concentration, dose administered, eye treated, and any wasted amount, so the J-code units and the JW or JZ wastage modifier match the chart exactly.

Prior authorization and step therapy

Many commercial and Medicare Advantage plans require documented bevacizumab failure or contraindication before covering branded anti-VEGF agents. Medicare fee-for-service generally does not. Authorization requested retroactively after a denial is rarely honored, so this has to happen before the injection.

IMPORTANT, and this correction matters because the usual advice sends you to the wrong rule: CMS-0057-F, the Interoperability and Prior Authorization Final Rule, took effect January 1, 2026 with decision timeframes of 7 calendar days standard and 72 hours expedited, plus a requirement to give a specific reason for denials. Those provisions exclude drugs. Anti-VEGF agents are drugs. So the 7-day and 72-hour clocks do not govern your anti-VEGF authorizations.

Also, the rule reaches Medicare Advantage organizations, Medicaid and CHIP fee-for-service, and Medicaid and CHIP managed care. Qualified Health Plan issuers on the federally facilitated exchanges are exempt from the timeframe requirement, which is often left out.

Drug prior authorization is addressed in a separate proposed rule, CMS-0062-P, with compliance proposed for October 1, 2027. Its proposed timeframes are not the same as CMS-0057-F: 24 hours for Medicaid and CHIP drug requests, and 72 hours standard with 24 hours expedited for QHP issuers. And its payer scope does not include Medicare Advantage, which is the payer type that matters most to a Medicare-heavy retina panel.

Until that is finalized, anti-VEGF authorization timelines are governed by plan policy. Keep a payer-specific matrix of who requires step therapy and what turnaround they actually deliver, and document step therapy explicitly: the prior agent, the response or lack of it, and any contraindication, written in language that mirrors the payer's own medical policy criteria.

Cataract surgery

The 2026 payment picture

The CY 2026 Physician Fee Schedule final rule (CMS-1832-F) was released October 31, 2025, effective January 1, 2026, and introduced two conversion factors: $33.5675 for qualifying APM participants and $33.4009 for non-qualifying participants, up 3.77% and 3.26% from the CY 2025 factor of $32.3465.

CMS also finalized a 2.5% efficiency adjustment, and it is worth stating precisely because the short version undersells it. The adjustment cuts work RVUs and the corresponding intra-service physician time for most non-time-based procedural and diagnostic codes. Exempt categories are time-based codes including E/M, care management, and behavioral health, telehealth-list codes, and maternity global codes.

For 66984, routine cataract extraction with IOL, the work RVU moved from 7.35 to 7.17. Combined with a reduction in facility practice expense allocation, ASCRS puts the 2026 payment at $462.94, an 11% decrease from $521.75 in 2025. The AMA reports 54% of ophthalmologists facing cuts under the combined changes.

Complex cataract, 66982

Payers want the operative note to name the specific complexity factor and connect it to a preoperative finding. Generic language downcodes.

Language that works: “4 mm pupil requiring four-quadrant iris retractors.” “Zonular dehiscence requiring capsular tension ring.” “Hypermature lens requiring conversion from phacoemulsification to extracapsular technique.”

Language that does not: “complicated case,” “difficult case.”

NOTE, two cautions on complexity factors that circulate as though they were settled:

The pediatric trigger in the CPT descriptor is a patient in the amblyogenic developmental stage requiring a primary posterior capsulotomy or capsulorrhexis. Anterior vitrectomy is not part of the descriptor and adding it to your attestation template does not strengthen the case.

Trypan blue staining is not a qualifying complexity factor on its own. Per AAO, some but not all MACs accept trypan blue use with a mature cataract diagnosis as supporting complex cataract. Dye use without a mature or hypermature lens is not accepted by most MACs. Putting trypan blue in a standardized attestation template as though it independently qualifies is audit bait, and it is the kind of thing that turns a defensible case into a pattern.

Check your own MAC's cataract LCD for the criteria you are actually subject to.

Global period modifiers

Cataract surgery carries a 90-day global. Track each patient's global start and end dates by eye in the PM system, because that is the fact the modifier choice turns on.

• Modifier 24. Unrelated E/M during the postoperative period.
• Modifier 58. Staged or related procedure planned at the time of the original surgery. Starts a new postoperative period.
• Modifier 78. Unplanned return to the operating or procedure room for a related complication. Pays the intraoperative portion only, roughly 70% of the full allowable, and does not start a new global period.
• Modifier 79. Unrelated procedure by the same physician during the postoperative period. Starts a new global period, paid in full.

YAG capsulotomy

66821 for posterior capsule opacification is where the modifier rules get applied backward most often.

Same eye, inside the 90-day cataract global: append modifier 78. This is separately payable, reimbursed at the intraoperative portion only. It is not “often bundled unless the payer requires 78.” Modifier 78 is not something a payer optionally requires. It is the mechanism that makes the service payable, and without it the claim looks like included follow-up.

Fellow eye: modifier 79, full payment, new global period.

More than 90 days out with no other global running: no modifier needed.

Premium IOLs, where the conventional advice is wrong

This section has three corrections and all three change what you actually do.

1. The authority is not NCD 239

“NCD 239” is the Medicare Coverage Database record number. The NCD itself is 80.12, Intraocular Lenses, effective May 19, 1997. Its operative content is that an IOL may be covered if reasonable and necessary. It says nothing about multifocal, toric, accommodating, or presbyopia-correcting lenses. It predates premium IOL technology by about a decade.

The actual authorities are CMS Ruling 05-01 (presbyopia-correcting IOLs, issued May 3, 2005) and CMS Ruling 1536-R (astigmatism-correcting IOLs, issued April 27, 2007), together with CMS's PC and AC IOL guidance. If your appeal letters cite NCD 239 for premium IOL non-coverage, a reviewer who pulls the NCD will find nothing in it supporting you.

You may also see a “CMS Ruling 05-05” referenced. I could not match that to any CMS ruling, so I would not cite it.

2. V2632 is the conventional lens code, not the premium code

V2632 is “posterior chamber intraocular lens.” That is the standard lens, and it is covered.

The non-covered premium function is identified with:

• V2787, astigmatism-correcting function of intraocular lens
• V2788, presbyopia-correcting function of intraocular lens

NOTE: ASC and hospital outpatient coders should not report V2632 at all, because the conventional lens is bundled into the facility payment. V2632 is a physician-office code.

Billing V2632 as though it were the premium lens is a straightforward code misidentification, and it is the single most common error I see repeated in ophthalmology reference material.

3. An ABN is not required for the premium upgrade

This one surprises people because it runs against the instinct that anything non-covered needs an ABN.

Per AAO: “No ABN is needed. Because the premium component of the IOL is statutorily excluded from Medicare coverage, no Advance Beneficiary Notice (ABN) is required.”

The ABN is the instrument for services denied as not reasonable and necessary. A statutory exclusion is a different category, and the premium function is statutorily excluded. Notice that the usual advice contradicts itself: it describes the upgrade as something “Medicare will never cover,” which is the definition of a statutory exclusion, and then prescribes the instrument for the other category.

What you should do instead: document informed financial consent with an itemized patient fact sheet showing the covered portion and the out-of-pocket upgrade cost, signed before surgery. A voluntary ABN or a Notice of Exclusion from Medicare Benefits is permissible if you want the paperwork, but it is not a compliance requirement, and treating it as one creates a false sense that the requirement is satisfied when the real requirement, informed financial consent, may not be.

What the patient may actually be charged

Under the CMS rulings, the beneficiary may be charged the portion of the facility and physician charges that exceeds the charge for insertion of a conventional IOL, plus the additional fitting and vision-testing resources the premium lens requires. Not more.

NCCI Chapter 8

Chapter 8 of the 2026 NCCI Policy Manual, revision date January 1, 2026, carries the ophthalmology bundling rules. The chapter is titled “Surgery: Endocrine, Nervous, Eye and Ocular Adnexa, and Auditory Systems,” covering CPT 60000 through 69999, with Section D as the ophthalmology portion. It is not an eye-only chapter.

The rules that matter most:

• Cataract extraction codes 66830 through 66991 are mutually exclusive of one another. Only one code from that range may be reported per eye.
• Injection of an antibiotic, steroid, or NSAID during cataract extraction is not separately reportable.
• Iridectomy, anterior vitrectomy, or trabeculectomy at the same encounter as cataract extraction is bundled unless separate and distinct for an unrelated reason, in which case an NCCI PTP-associated modifier and clear documentation of distinct medical necessity are required. Minimal vitreous loss during routine cataract extraction is bundled.
• 67028 is not separately reportable with paracentesis (65800 through 65815) or subconjunctival injection (68200) on the same eye at the same encounter.

IMPORTANT on that last one: the NCCI language is same-eye and ipsilateral. Dropping the laterality qualifier turns a same-eye edit into a blanket prohibition and will cause you to under-bill legitimate contralateral services.

Diagnostic imaging frequency

The retinal imaging codes are differentiated by who reviews the image, not by whether the encounter is a screening:

• 92227 with remote clinical staff review and report
• 92228 with remote physician or other qualified health care professional interpretation and report
• 92229 point-of-care autonomous analysis and report

IMPORTANT: the once-per-12-months rule that circulates for all three is sourceable for 92227 only. Noridian's article A58914 states Noridian will not pay 92227 more frequently than annually, and that 92227 should not be billed if the patient has already had an in-person ocular examination by an ophthalmologist in that period.

92228 is the code used for patients with known or active retinal disease. Applying a screening frequency cap to it inverts its purpose. So “once retinopathy is diagnosed the code no longer applies” is right for 92227 and wrong for 92228.

Check your own MAC's article before applying any frequency rule, since this is MAC-level policy rather than national.

Require a specific clinical indication and diagnosis code on every diagnostic imaging order, for 92133, 92134, 92227, 92228, 92229, 92250, 92201, and 92202. “Routine follow-up” is not an indication.

The denial patterns you will actually see

These are the recurring ones. I am not ranking them, because no published dataset ranks ophthalmology denial causes and I would rather say that than make up an order.

Missing or mismatched laterality on 67028 | CARC 4 (“The procedure code is inconsistent with the modifier used”), CARC 16 (“Claim/service lacks information or has submission/billing error(s)”). Fix with a hard scrubber edit.

Anti-VEGF drug denied for authorization or step therapy | CARC 197 (“Precertification/authorization/notification/pre-treatment absent”), CARC 50 (“These are non-covered services because this is not deemed a 'medical necessity' by the payer”). Fix upstream with the payer matrix and documented step therapy.

66982 without named complexity | CARC 50, CARC 16. Fix in the operative template, carefully, per the cautions above.

Premium IOL billed as covered | CARC 96 (“Non-covered charge(s)”), CARC 50. Fix with correct code selection (V2787 or V2788, not V2632) and itemized financial consent.

Global period modifier misuse | CARC 97 (“The benefit for this service is included in the payment/allowance for another service/procedure that has already been adjudicated”), CARC 4. Fix with a global tracker by patient and eye.

Retinal imaging over frequency | CARC 119 (“Benefit maximum for this time period or occurrence has been reached”), CARC 96. Fix by checking for an existing retinopathy diagnosis before scheduling, and by applying the frequency rule to the right code.

Practices that prevent the denial

1. Name a specific complexity factor in every 66982 note, tied to a preoperative finding, using the language above rather than a generic phrase.
2. Record the full drug administration detail on every injection, so units and wastage modifiers match the chart.
3. Maintain a global period tracker by patient and by eye, with the surgery date, the window end date, and anything scheduled inside it.
4. Keep itemized financial consent on file for every premium IOL case, signed before surgery, showing the covered portion and the upgrade separately.
5. Require a specific clinical indication on every imaging order.
6. Scrub every 67028 line for laterality before submission.
7. Document step therapy explicitly before starting a branded anti-VEGF agent.

Frequently asked questions

How we work on this at ROI

Ophthalmology denials are patterned tightly enough to catch before submission.

• The platform ingests 835 and 837 files from any clearinghouse or EHR export and maps laterality, global period, and drug-pairing denial patterns to the right category.
• Step therapy gaps are flagged against a payer matrix rather than discovered on the remittance.
• The EDI Code Intelligence Lab carries every CARC and RARC common in ophthalmology with fix, appeal, and prevention guidance.
• The appeal template library includes laterality corrections, complex cataract documentation appeals, and global period modifier disputes.

If you want to see where your own denials concentrate first, the revenue health assessment is free.

Three things worth checking this week

1. Your premium IOL charge master. If V2632 is mapped as the premium lens, that is today's fix.
2. Your anti-VEGF drug list. If it stops at four J-codes, you are missing J0177, J2779, and ten biosimilars.
3. Whether your appeal templates cite NCD 239 for premium IOL non-coverage. Replace it with CMS Ruling 05-01 and CMS Ruling 1536-R.

If something here does not match what your MAC is doing, tell me. Local policy varies more in this specialty than in most, and I would rather know.

Sources

1. Centers for Medicare & Medicaid Services. 2026 NCCI Medicare Policy Manual, Chapter 8.
2. Centers for Medicare & Medicaid Services. CY 2026 Medicare Physician Fee Schedule Final Rule Fact Sheet (CMS-1832-F).
3. ASCRS. 2026 Medicare Physician Fee Schedule Final Rule Released.
4. American Medical Association. What to Expect from the 2026 Medicare Physician Fee Schedule.
5. Centers for Medicare & Medicaid Services. Interoperability and Prior Authorization Final Rule (CMS-0057-F).
6. Centers for Medicare & Medicaid Services. 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P).
7. Wellpoint Federal. Local Coverage Article A52451, Billing and Coding: Ranibizumab, Aflibercept and biosimilars.
8. Centers for Medicare & Medicaid Services. NCD 80.12, Intraocular Lenses.
9. Centers for Medicare & Medicaid Services. Guidance on presbyopia-correcting and astigmatism-correcting IOLs.
10. American Academy of Ophthalmology. Premium IOLs: A Legal and Ethical Guide.
11. American Academy of Ophthalmology. Complex Cataract Surgery.
12. American Academy of Ophthalmology. YAG Laser When Performed in Global Period.
13. Noridian Healthcare Solutions. Local Coverage Article A58914, retinal imaging frequency.
14. X12.org. Claim Adjustment Reason Codes.